> Back to EJC

Recent editions

  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.
  • November 2015
    Caroline Robert on new developments in immunotherapy.
  • October 2015
    Milena Sant on the latest results from the EUROCARE study.
  • September 2015
    The science behind the IARC code that could reduce cancer in Europe.
  • July/August 2015
    Thomas Helleday on an exciting new class of drug, MTH1 inhibitors.
  • June 2015
    Lesley Seymour and Jan Bogaerts on the future of RECIST.
  • May 2015
    Paul Workman on strategies for overcoming resistance to new drugs.
  • April 2015
    Highlights from the TAT Congress in Paris.
  • March 2015
    Christopher Wild on the exposome, a measure of environmental exposure.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – September 2013

Loading EJC News Focus video

EJC's Drug of the Year, 2013

Immunotherapy is finally emerged from the shadows as a realistic – and perhaps essential – tool in cancer control. After decades of painstaking research which yielded little benefit for patients, immunotherapy has entered a fresh phase with the development of new agents that can either activate the immune system or re-awaken silenced immune responses to a tumour.

The emerging paradigm, by which only the most effective immune cells are selectively harnessed to target the tumour, is an immediate advance for patients. It also holds the promise of future steps forward, as clinicians and researchers learn how best to use the new agents in combination.

In this month's EJC News Focus, Jean-Charles Soria and Caroline Robert, both from Institut Gustave Roussy, Paris-Sud, France, explain to Helen Saul why the Programmed Death-1 receptor (PD-1), and its ligand (PD-L1), have been recognised in EJC's Drug of the Year article, 2013.